About Alport Syndrome
Alport syndrome is a progressive nephropathy caused by pathogenic variants in genes encoding type IV collagen alpha chains, which are essential structural components of the glomerular basement membrane, cochlea, and ocular lens. The hallmark is persistent microscopic haematuria progressing to proteinuria, declining GFR, and end-stage kidney disease, typically earlier in males with X-linked disease. Sensorineural hearing loss and characteristic ocular findings (anterior lenticonus) complete the classic triad.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Alport Syndrome trials.
Current eGFR, urine protein-to-creatinine ratio, and kidney biopsy showing thinning or lamellation of the GBM on electron microscopy are standard eligibility documents — have these ready.
X-linked vs. autosomal inheritance affects trial eligibility; confirm molecular diagnosis specifying which COL4A gene is affected and the inheritance pattern.
Patients already on ACE inhibitors or ARBs should note dosing, as trials may require stable background therapy or specific washout before enrolment.
Patient Resources
Find recruiting Alport Syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Alport Syndrome. Updated daily.